Important Note to Reader: The information in these Web pages is for your general knowledge and background only. Note that these Web pages contain information from various sources considered to be dependable. However, we make no representations, warranties or other expressed or implied warranties or guarantees regarding the accuracy, reliability or completeness of the information. Under no circumstance shall Gyrus ACMI, Inc., Olympus America Inc. and/or its or their respective affiliates, employees, consultants, agents or representatives (collectively "Gyrus") be liable for any costs, expenses, losses, claims, liabilities or other damages (whether direct, indirect, special, incidental, consequential or otherwise) that may arise from or be in incurred in connection with the information provided or any use thereof.
© 2010 Gyrus ACMI, Inc. All rights reserved. | Privacy Policy | Legal Notice
Tailored hormone therapy improves postoperative endometriosis outcomes
October 3rd 2024A recent study suggests that postoperative endometriosis patients experience improved quality of life through hormone therapies guided by optimizing treatment based on individual hormonal receptor profiles.
Read More
Study reports reduced SSI odds after gynecologic surgery from metronidazole and cefazolin
September 19th 2024A recent study shows that adding metronidazole to cefazolin significantly lowers the risk of surgical site infections in gynecologic cancer surgeries, enhancing patient outcomes.
Read More
Study: Pelvic floor dilator reduces pelvic floor muscle injury during vaginal delivery
August 6th 2024A new pilot study published in the International Urogynecology Journal found that Materna Medical’s Prep Device, a pelvic floor dilator, reduced full levator ani muscle avulsion during vaginal delivery in first-time mothers.
Read More